Tysabri Means Everything to Biogen and Elan ... for Now

It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec (Nasdaq: BIIB  ) and Elan (NYSE: ELN  ) .

Onyx Pharmaceuticals (Nasdaq: ONXX  ) lives and dies by sales of Nexavar, but it's not that important to partner Bayer, which has other drugs up its sleeve. When the Food and Drug Administration refused to review Roche's marketing application for T-DM1, it stung a little for Roche, but ImmunoGen (Nasdaq: IMGN  ) , which is due royalties on the sales, fell 35%.

When drug partnerships are involved, there's usually a big guy and a little guy. But in this case it's two medium-sized guys strapped to the coattails of Tysabri.

Fortunately, those tails are still holding strong. Sales of Tysabri were up 20% in the first quarter, which allowed Biogen to post a 9% gain in revenue and Elan to hold revenue flat despite declining sales of multiple legacy products.

To keep the momentum, Biogen and Elan have to bring their test for the JC virus to market. The virus causes a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML, in patients whose immune systems are tuned down by Tysabri. The test will cause some JC-virus-positive patients to stop taking the drug, but the expectation is that there are many more JC-virus-negative patients that aren't taking Tysabri simply because they think the unknown risk is too high.

Act 2
While Tysabri is immensely important to both companies right now, neither company is resting on its laurels.

Biogen is developing an oral multiple sclerosis drug, BG-12, which passed its first trial and the initial data look really good.

Elan has an Alzheimer's disease drug, bapineuzumab, in phase 3 development in combination with Johnson & Johnson (NYSE: JNJ  ) and Pfizer (NYSE: PFE  ) . It's a disease area filled with failures, but that also means a success will be an instant blockbuster.

Biogen's and Elan's investors will need to keep their heads on a swivel, keeping track of both Tysabri sales as well as the upcoming drugs to take its place.

Keep track of Biogen and Elan as they try to keep expanding sales of their most-important drug. Click on their names to add them to My Watchlist, which will help you keep track of all our Foolish analysis on the companies.

Johnson & Johnson and Pfizer are Motley Fool Inside Value picks. Elan and ImmunoGen are Motley Fool Rule Breakers choices. Johnson & Johnson is a Motley Fool Income Investor pick. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1479668, ~/Articles/ArticleHandler.aspx, 7/28/2014 3:10:23 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement